These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 16109563)
1. [Dynamic analysis of drug resistance of Pseudomonas aeruginosa in laboratory and clinical two-drug regimen]. Tian BW; Yang YJ; Pang XY Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):1009-11. PubMed ID: 16109563 [TBL] [Abstract][Full Text] [Related]
2. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units. Vojtová V; Kolár M; Hricová K; Uvízl R; Neiser J; Blahut L; Urbánek K New Microbiol; 2011 Jul; 34(3):291-8. PubMed ID: 21811750 [TBL] [Abstract][Full Text] [Related]
3. [Analysis of drug resistance of Pseudomonas aeruginosa and use of antibiotics in burn wards during 6 years]. Dou Y; Zhang Q Zhonghua Shao Shang Za Zhi; 2014 Feb; 30(1):9-14. PubMed ID: 24684983 [TBL] [Abstract][Full Text] [Related]
4. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance]. Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699 [TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa: Evaluation of Pathogen Burden and Drug-Resistance Trends in a Tertiary Care Hospital. Saeed M; Rasheed F; Afzal RK; Hussain S; Riaz S; Ahmad A J Coll Physicians Surg Pak; 2018 Apr; 28(4):279-283. PubMed ID: 29615167 [TBL] [Abstract][Full Text] [Related]
6. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR J Antimicrob Chemother; 2005 Aug; 56(2):353-9. PubMed ID: 15967767 [TBL] [Abstract][Full Text] [Related]
7. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics]. Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430 [TBL] [Abstract][Full Text] [Related]
8. Antibiotic susceptibility patterns of Pseudomonas aeruginosa to available antipseudomonal drugs in Ibadan, Nigeria. Ogbolu DO; Ogunledun A; Adebiyi OE; Daini OA; Alli AO Afr J Med Med Sci; 2008 Dec; 37(4):339-44. PubMed ID: 19301711 [TBL] [Abstract][Full Text] [Related]
10. Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both. Xiong YQ; Caillon J; Zhou XY; Potel G; Bugnon D; Le Conte P; Le Gallou F; Le Floch R; Baron D; Drugeon H J Antimicrob Chemother; 1995 May; 35(5):697-706. PubMed ID: 7592185 [No Abstract] [Full Text] [Related]
12. [Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens]. Sacha PT; Jakoniuk P; Wieczorek P; Zalewska M; Leszczyńska K Med Dosw Mikrobiol; 2004; 56(3):263-73. PubMed ID: 15773503 [TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. Shortridge D; Pfaller MA; Castanheira M; Flamm RK Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729 [TBL] [Abstract][Full Text] [Related]
15. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam. Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan. Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693 [TBL] [Abstract][Full Text] [Related]
17. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China]. Wang H; Chen MJ; Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914 [TBL] [Abstract][Full Text] [Related]
18. The peculiarities of Pseudomonas aeruginosa resistance to antibiotics and prevalence of serogroups. Gailiene G; Pavilonis A; Kareiviene V Medicina (Kaunas); 2007; 43(1):36-42. PubMed ID: 17297282 [TBL] [Abstract][Full Text] [Related]
19. In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa. Yasmin F; Akhtar N; Hameed A Pak J Pharm Sci; 2013 Sep; 26(5):1041-4. PubMed ID: 24035966 [TBL] [Abstract][Full Text] [Related]
20. [Epidemiology and drug susceptibility of Pseudomonas aeruginosa strains isolated in the Chugoku region of Japan. Infection Forum in the Chugoku Region]. Kuwabara M; Kusano N; Shimizu E; Shimizu W; Kobayashi K; Koda S; Doi M; Sugai M; Kumon H Jpn J Antibiot; 2011 Apr; 64(2):97-108. PubMed ID: 21721248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]